Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 10 · below the Ichimoku cloud · RSI 44 · MACD above its signal
None of the 29 investors followed here reported a position in ACHFF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ACHFF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -13.4 | -23.9 | -43.5 | -2.1 | -1.6 | 72.9 | 4.6 | 27.4 | -17.8 | -3.9 | −34.7% | ||
| 2025 | -6.7 | 0.0 | -1.6 | -3.2 | 7.7 | 0.5 | -6.0 | -0.7 | -23.8 | -23.4 | 5.2 | 18.5 | −34.6% |
| 2024 | -1.5 | 0.0 | 50.0 | -21.8 | -4.7 | -0.8 | -13.9 | 1.0 | 22.6 | 3.1 | 4.5 | -3.6 | +20.9% |
| 2023 | -0.5 | -23.7 | 6.3 | -9.5 | -9.9 | 8.8 | 5.4 | -22.0 | -33.9 | -7.5 | 38.9 | 7.4 | −46.3% |
| 2022 | -4.7 | 0.8 | 26.5 | -8.1 | -25.7 | 2.6 | 17.9 | -7.6 | -14.5 | 8.7 | -9.3 | -3.3 | −24.4% |
| 2021 | -11.6 | -2.7 | 4.9 | 0.0 | 10.7 | -6.4 | 8.8 | 22.0 | -2.2 | 68.4 | 59.4 | -24.7 | +145.5% |
| 2020 | -3.8 | -12.5 | 5.7 | 43.1 | 6.5 | 7.5 | -3.2 | -1.0 | -2.0 | 21.5 | -7.0 | -0.9 | +53.2% |
| 2019 | 8.8 | -8.1 | 7.9 | 3.1 | -7.4 | -1.7 | -2.2 | -15.7 | -1.9 | 2.6 | -6.0 | 3.0 | −18.7% |
| 2018 | 31.5 | 1.7 | 3.1 | 25.7 | 18.5 | 19.2 | 32.1 | 15.0 | -8.0 | -8.7 | -4.4 | -16.8 | +148.3% |
| 2017 | 0.0 | 5.4 | 0.0 | 0.0 | 0.0 | 10.9 | 0.0 | -6.8 | 2.6 | -8.3 | 6.3 | 6.5 | +16.0% |
| 2016 | 52.4 | -17.6 | 45.5 | 0.0 | 0.0 | 0.0 | 2.8 | 0.0 | 0.0 | -22.6 | 7.8 | -6.0 | +47.2% |
| 2015 | 0.0 | 0.0 | -4.7 | -28.8 | 34.5 | 0.0 | 0.0 | -12.8 | -2.9 | -0.4 | 0.0 | -7.8 | −29.1% |
| 2014 | 0.0 | 0.0 | 0.0 | 5.5 | 0.8 | -42.2 | 0.0 | 0.0 | 1.4 | 0.0 | 103.4 | 0.0 | +26.7% |
| 2013 | -24.7 | 0.0 | 29.6 | 0.0 | 0.0 | 0.0 | 0.0 | -18.3 | 0.0 | 0.0 | 0.0 | 0.0 | −20.3% |
| 2012 | 0.0 | 0.0 | 0.0 | -0.8 | 0.0 | -21.5 | 0.0 | 0.0 | 0.0 | 0.0 | -3.3 | 0.0 | −24.7% |
| 2011 | 0.9 | 11.3 | -22.8 | 23.9 | 0.0 | -37.2 | 31.6 | -20.3 | 1.0 | 25.6 | 0.0 | -37.4 | −43.9% |
| 2010 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 241.5 | +241.5% |
| 2009 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 860.9 | -7.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +791.3% |
| 2008 | 0.0 | 0.0 | 0.0 | -32.5 | 0.0 | 44.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -70.5 | −71.2% |
| 2007 | 0.0 | 0.0 | 0.0 | 0.0 | -43.8 | -20.3 | 53.2 | 11.1 | 0.0 | 0.0 | 0.0 | 0.0 | −23.8% |
No insider transactions reported for ACHFF.
No analyst coverage for this instrument.
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.